Summary & Overview
HCPCS C9445: Injection, Recombinant C1 Esterase Inhibitor (Ruconest), 10 Units
HCPCS Level II code C9445 denotes the injection of recombinant C1 esterase inhibitor, Ruconest, in 10-unit increments. This biologic agent is used for replacement therapy in conditions requiring C1 esterase inhibitor, and the HCPCS code enables standardized billing for administration of the product in facility-based infusion and outpatient settings. Nationally, clear coding for high-cost biologics like Ruconest matters for claims processing, utilization monitoring, and payer coverage determinations.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical service represented by the code, typical sites of service, and the types of benchmarks and policy elements commonly associated with specialty biologic injections. The publication outlines payment benchmarking context, common coverage considerations for infusion-administered biologics, and potential policy updates that affect coding and reimbursement workflows. It also situates C9445 in clinical context for providers and billing staff responsible for facility-based administration of recombinant C1 esterase inhibitor.
Billing Code Overview
HCPCS Level II code C9445 describes the administration of injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units. This service represents use of a recombinant C1 esterase inhibitor product supplied in 10-unit dosing increments for replacement therapy.
-
Service type: Injectable biologic therapy
-
Typical site of service: Hospital outpatient department, ambulatory infusion center, specialty clinic, or other facility-based infusion setting
Data not available in the input for modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with hereditary angioedema (HAE) presenting to an infusion center or emergency department with acute angioedema symptoms such as progressive non-pitting swelling of the face, extremities, oral mucosa, or larynx, or with severe abdominal pain from visceral edema. The provider documents the need for a specific C1 esterase inhibitor replacement therapy. The clinical workflow includes triage assessment, verification of patient identity and indication, review of prior authorization and insurance coverage, preparation and reconstitution of C9445 (injection, c-1 esterase inhibitor [recombinant], Ruconest, 10 units), administration by intravenous bolus or infusion per product instructions, monitoring for immediate hypersensitivity or infusion reactions for at least 30–60 minutes, documentation of lot number and units administered, and discharge instructions with follow-up arranged with the patient’s specialty clinic. Billing is submitted using HCPCS code C9445 with appropriate diagnosis code(s) supporting HAE and any required modifiers for place of service or payer-specific billing rules.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when only the physician professional portion of a service is billed (rare for drug administration; generally not used for ). |